Sponsors move to postpone medical-spa patient-safety bill after regulators urged to lead work

Senate Bill 130, offered by Senator Kipp and co-prime sponsor Senator Frizzell, was brought before the Senate Health and Human Services Committee with a stated goal of addressing patient-safety gaps in the growing medical spa and wellness industry.

Senator Kipp told the panel the bill aimed to create consistent safeguards where prescription medications are used outside traditional clinical settings. He said stakeholders raised a broad set of concerns and requested exemptions that, if accepted, would significantly narrow the bill’s reach. "What we have learned is that this issue is more complex than a single piece of legislation can address effectively," Kipp said, urging a coordinated regulatory response.

Senator Frizzell said the committee’s review revealed broader questions about oversight and credentialing and recommended the Department of Regulatory Agencies (DORA) lead a more comprehensive framework. "This is an opportunity to step back and pursue a more thoughtful approach that prioritizes transparency, strengthens consumer protections, and ensures appropriate oversight across this growing industry," Frizzell said, and then moved to postpone the bill indefinitely.

Senator Weisman and others agreed that existing consumer-protection tools, including the state Consumer Protection Act and the attorney general's office, offer enforcement options today, but that additional rulemaking or statutory clarity may be needed to address credentialing and cross‑sector oversight.

The committee approved the sponsors’ motion to postpone SB 130 indefinitely with no recorded opposition.

Next steps: the sponsors said they will continue stakeholder engagement and coordination with DORA and providers before returning with an alternate approach.